BioSpace News Archive

Business

Renalytix Reports Full Year Fiscal 2021 Results

Renalytix plc announces its results for the twelve months ended 30 June 2021.

October 21, 2021
·
65 min read
Business

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

IQVIA Holdings Inc. today reported financial results for the quarter ended September 30, 2021.

October 21, 2021
·
20 min read
BioCapital

University of Maryland School of Medicine Neurology Chair Peter B. Crino, MD, PhD, Receives Prestigious Neuroscience Award

University of Maryland School of Medicine Dean E. Albert Reece, MD, PhD, MBA announced that Peter B. Crino, MD, PhD, Professor and Chair of UMSOM’s Department of Neurology, has received the Javits Neuroscience Investigator Award, which provides $2.7 million in total funding.

October 21, 2021
·
5 min read
Business

Nephros Announces Third Quarter 2021 Financial Results Conference Call

Nephros, Inc. today announced that it will file its third quarter financial results on Thursday, November 4, 2021 after market close and will host a conference call that same day at 4:30 PM ET.

October 21, 2021
·
1 min read
BioCapital

OpGen Subsidiary Ares Genetics Launches AREScloud

OpGen, Inc today announced that its subsidiary Ares Genetics has commercially launched its AREScloud web application.

October 21, 2021
·
6 min read
Business

Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation today announced that it has scheduled its third quarter 2021 financial results and corporate update for Thursday, November 4, 2021.

October 21, 2021
·
2 min read
FDA

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

Intellia Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis.

October 21, 2021
·
7 min read
Drug Development

First Wave BioPharma Forms Steering Committee for Phase 2a PASSPORT Clinical Trial to Evaluate FW-ICI-AC in Cancer Patients with Immune Checkpoint Inhibitor-Associated Colitis

First Wave BioPharma, Inc., today announced the initial members of the steering committee for PASSPORT, the Company’s Phase 2a clinical trial investigating FW-ICI-AC as a treatment for Grade 1 and Grade 2 colitis and diarrhea

October 21, 2021
·
13 min read
BioMidwest

Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit

Abeona Therapeutics Inc. today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021, at 3:30 p.m. ET.

October 21, 2021
·
3 min read
Drug Development

PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based CombinationTemporary administrative suspension of recruitment

PDS Biotechnology Corporation today announced the temporary suspension of recruitment in the National Cancer Institute (NCI)-led Phase 2 clinical trial (NCT04287868) evaluating PDS0101 (Versamune ® -HPV16) in combination with two investigational immune-modulating agents in advanced HPV cancers.

October 21, 2021
·
6 min read